GB202204884D0 - Sirna targeting kcna1 - Google Patents

Sirna targeting kcna1

Info

Publication number
GB202204884D0
GB202204884D0 GBGB2204884.7A GB202204884A GB202204884D0 GB 202204884 D0 GB202204884 D0 GB 202204884D0 GB 202204884 A GB202204884 A GB 202204884A GB 202204884 D0 GB202204884 D0 GB 202204884D0
Authority
GB
United Kingdom
Prior art keywords
kcna1
sirna targeting
sirna
targeting
targeting kcna1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2204884.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondo Ricerca Medica Srl
Original Assignee
Fondo Ricerca Medica Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondo Ricerca Medica Srl filed Critical Fondo Ricerca Medica Srl
Priority to GBGB2204884.7A priority Critical patent/GB202204884D0/en
Publication of GB202204884D0 publication Critical patent/GB202204884D0/en
Priority to PCT/EP2023/058900 priority patent/WO2023194412A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
GBGB2204884.7A 2022-04-04 2022-04-04 Sirna targeting kcna1 Ceased GB202204884D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2204884.7A GB202204884D0 (en) 2022-04-04 2022-04-04 Sirna targeting kcna1
PCT/EP2023/058900 WO2023194412A1 (en) 2022-04-04 2023-04-04 Sirna targeting kcna1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2204884.7A GB202204884D0 (en) 2022-04-04 2022-04-04 Sirna targeting kcna1

Publications (1)

Publication Number Publication Date
GB202204884D0 true GB202204884D0 (en) 2022-05-18

Family

ID=81581329

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2204884.7A Ceased GB202204884D0 (en) 2022-04-04 2022-04-04 Sirna targeting kcna1

Country Status (2)

Country Link
GB (1) GB202204884D0 (en)
WO (1) WO2023194412A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2813582T3 (en) 2000-12-01 2017-07-31 Max-Planck-Gesellschaft Zur Förderung Der Wss E V Small RNA molecules that mediate RNA interference
US20180000953A1 (en) 2015-01-21 2018-01-04 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3247398A4 (en) 2015-01-23 2018-09-26 Moderna Therapeutics, Inc. Lipid nanoparticle compositions

Also Published As

Publication number Publication date
WO2023194412A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
EP4058484A4 (en) Antigen-binding proteins targeting shared neoantigens
IL290499A (en) Extracellular vesicle-aso constructs targeting stat6
EP3781196A4 (en) Sequence-specific in vivo cell targeting
EP4017503A4 (en) Ddx17 and nlrc4 targeting for inflammatory diseases
IL275903A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
GB202002119D0 (en) Delivery optimisation
IL286238A (en) Antibodies targeting c5ar
IL275902A (en) Antisense oligonucleotides targeting alpha-synuclein and uses thereof
IL280581A (en) Variant rnai against alpha-synuclein
EP4061254A4 (en) Targeting guides
IL292065A (en) Variant igf2 constructs
EP3633036A4 (en) Antisense nucleic acid targeting pcsk9
EP4077354A4 (en) Novel cellular delivery methods
GB202014751D0 (en) Targeting vector
GB202204884D0 (en) Sirna targeting kcna1
IL304679A (en) Antisense oligonucleotides increasing foxg1 expression
GB201905301D0 (en) Gene therapy
IL292718A (en) Cancer treatments targeting cancer stem cells
EP4043038A4 (en) Sirna expression vector
GB202002202D0 (en) Gene therapy
GB201907802D0 (en) Cigarillo
GB202311983D0 (en) Stats sirna
GB202308779D0 (en) Aptamer
GB202103243D0 (en) Targeting peptide
CA213706S (en) Goggles

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)